 NEW YORK, April 19, 2021 GLOBE NEWSWIRE -- Protara Therapeutics, Inc. Nasdaq: TARA, a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced the appointment of Martín Sebastian Olivo, M.D. as Chief Medical Officer, effective immediately. Dr. Olivo brings to Protara more than 15 years of experience in oncology translational and clinical research and global drug development, most recently serving as Vice President, Breast Cancer Clinical Development Lead at Gilead Sciences, Inc. formerly Immunomedics, Inc.. 